BioWorld

March 17, 2008

Transition Could Get $130M in Diabetes Deal With Lilly

Transition Therapeutics Inc. could receive up to $137 million in a deal with drug giant Eli Lilly and Co., which will acquire rights to Transition's gastrin-based therapies for diabetes. (BioWorld Today) Read More

Legislation Would Create Path for Follow-on Biologics Work

T-Cell Gene is Linchpin for Breast Cancer Metastasis

Investigations Looming in Off-Label Promotion

Corrections & Clarifications

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...